Mizuho Securities Ponders How CMS Reimbursement Might Affect EXACT Sciences Corporation

In a report published Friday, Mizuho Securities analyst Peter Lawson reiterated a Buy rating and $22.00 price target on EXACT Sciences Corporation (NASDAQ: EXAS).

In the report, Mizuho Securities noted, “Last night CMS issued preliminary reimbursement of $502 for Cologuard, above the approximately $350 we believe were in consensus sell-side models, and above the $400 from our investor survey — in line with Exact's proposal. The preliminary decision is a major positive for the stock and removes one of the two major elements from the bear thesis - uptake/commercializing being the second. We expect a 30-day comment period before a final pricing decision is made by year-end.”

EXACT Sciences Corporation closed on Thursday at $18.12.